Breast Cancer, PR and HER2

ER+ and PR+ Breast Cancer: Key Statistics and Molecular Insights
ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements.
First Patients Enrolled in Trial on Anti-HER2 Therapy in HER2+ Breast Cancer
The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ breast cancer using circulating tumor DNA.
Vepdegestrant Beneficial in ER+/HER2- Breast Cancer With ESR1 Mutations
Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.
Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patients
Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, vepdegestrant, has seen mixed results after it was only able to extend progression-free survival (PFS) in certain patients in a Phase III trial.
Dr. Kevin Kalinsky Covers Targeted Therapy in HER2– Breast Cancer
Dr. Kevin Kalinsky discusses the role of targeted therapy and clinical decision-making in managing estrogen-driven, HER2-negative breast cancer.
Arvinas Plummets 53% On Mixed Results For Its Pfizer-Tied Breast Cancer Drug
Arvinas stock lost half its value Tuesday after the biotech company reported mixed results from its Pfizer-partnered breast cancer drug.
Understanding Metastatic Breast Cancer: An In-Depth Look
Metastatic breast cancer is complex, requiring holistic care and ongoing treatment, with varying prognosis depending on ...
WebMD1d
Advanced HER2-Negative Breast Cancer Treatments
When there are higher than normal amounts of HER2 on breast cancer cells, the cancer is called HER2 positive. And these cancer cells can grow more rapidly than other breast cancers.
Where Does Breast Cancer Most Commonly Spread?
The peritoneal cavity, which contains the abdominal organs, is a less common but still potential site for breast cancer to ...
Targeted Oncology1d
HER2DX Test Transforms Treatment Decisions in HER2+ Breast Cancer
A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.
Fierce Biotech2d
Pfizer, Arvinas post mixed breast cancer survival results in first phase 3 test for a PROTAC degrader
The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...
On Her Mind: State representative working to close gaps in women's healthcare while battling breast cancer
Less than two months ago, 52-year-old Oklahoma State Representative Melissa Provenzano underwent a mastectomy for stage one ...
WebMD13d
Treatment for HER2-Negative Advanced Breast Cancer
When you have HER2-negative advanced (metastatic) breast cancer, treatment usually focuses on managing your disease, not curing the cancer. The goal is to help you live longer and have a ...
PharmExec1d
Phase III Trial Data Show Vepdegestrant Produces Encouraging Outcomes in ER+/HER2- Advanced or Metastatic Breast Cancer
Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER+ ...